

Bone metastases are a common and debilitating complication in advanced breast cancer, often leading to skeletal-related events (SREs) such as fractures, spinal cord compression, and the need for radiation or surgery.

XGEVA® (denosumab), a fully human monoclonal antibody targeting RANKL, has demonstrated significant clinical benefits in reducing the incidence of SREs, delaying their onset, and improving patients' quality of life compared with zoledronic acid.

The newly introduced XGEVA® pre-filled syringe (PFS) formulation offers the same therapeutic efficacy as the traditional vial, while providing several practical advantages. The PFS ensures more precise dosing, minimizes drug preparation steps, and reduces the risk of dosing errors or contamination during handling. Its ready-to-use design also streamlines administration, saving time for healthcare providers and enhancing patient safety.

These improvements make XGEVA® PFS an important advancement for optimizing supportive care in breast cancer patients with bone metastases, enabling effective skeletal protection with greater convenience and safety in clinical practice.